Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Moderately Ill Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia

NCT04901676 is registered in ClinicalTrials.gov with Hospital Israelita Albert Einstein as lead sponsor.

NCT NCT04901676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04901676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Moderately Ill Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia
Lead sponsor
Hospital Israelita Albert Einstein
Phase
Phase 3
Overall status
Suspended
Start date
September 9, 2021
Completion date
February 28, 2023
Enrollment
612 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia